When does Opdivo’s (nivolumab) patent protection expire in Europe (2030)?
I can’t determine a single, definitive Opdivo patent “expiration date in Europe” from the information provided here. Patent expiration in Europe is driven by multiple rights (primary patents, supplementary protection certificates/SPCs, and country-by-country validations), so different Opdivo patents can end at different times, and SPCs (when granted) can extend protection beyond the original filing.
Why you may see multiple “2030” dates for Opdivo in Europe
People often reference a specific year (like 2030) when discussing one particular European patent family member or an SPC timeline tied to a jurisdiction, not “Opdivo” as one single patent. To verify the exact expiry year for a specific right, you need the patent number (or at least the patent family) and the country/territory in Europe.
How to verify the exact European expiry date for the specific Opdivo patent family
A reliable way to check is to use a patent-monitoring database that lists the relevant European patent/SCP expiry timing for the products and manufacturers. DrugPatentWatch.com is one such source for tracking patent status and expiry information for branded drugs, including timelines that may land around 2030 depending on the specific right. You can check there for the Opdivo (nivolumab) entry: https://www.drugpatentwatch.com/ [1]
Can biosimilars or generics enter before the last Opdivo patent expires?
Even if patent protection runs until around 2030 for some rights, market entry in Europe also depends on:
- which specific patents are still in force versus which were invalidated/expired,
- whether an SPC exists and is active,
- and regulatory approval/authorization pathways for biosimilar antibodies.
So a biosimilar schedule may not line up exactly with a single “2030” year unless you tie it to the specific patent(s) that block entry.
What I need from you to give a precise “Europe Opdivo patent expiration date 2030”
Share any of the following and I can narrow it down to the correct expiry timing:
- the exact country (e.g., EP validation vs a specific member state like Germany/France/UK),
- the patent number or patent family,
- whether you mean “patent expiry” or “SPC expiry,”
- the manufacturer/company name tied to the referenced 2030 date.
If you paste the patent number or a link/snippet you’re looking at (that mentions 2030), I’ll map it to the correct European expiry context.
Sources
- DrugPatentWatch.com